The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1

Authors: Yue Xi, Yanping Li, Pengfei Xu, Sihan Li, Zhengsheng Liu, Hung-chun Tung, Xinran Cai, Jingyuan Wang, Haozhe Huang, Menglin Wang, Meishu Xu, Songrong Ren, Song Li, Min Zhang, Yong J. Lee, Leaf Huang, Da Yang, Jinhan He, Zhiying Huang, Wen Xie

Published: 2021-09-03

DOI: 10.1126/sciadv.abg9241

Source: Full article

---

Abstract

Pirfenidone inhibits HSC activation and liver fibrosis by targeting glutaredoxin-1 and reducing Smad3 glutathionylation.